JSR Life Sciences Expands Enters Commercial Partnership with Natrix Separations for Global Distribution

JSR Life Sciences Expands Enters Commercial Partnership with Natrix Separations for Global Distribution

Missy Bindseil, 408-543-8945orMolly McGlaughlin, 617-548-7927

JSR Life Sciences announced today that it has entered into a global distribution agreement for the commercialization of Natrix Separations’ products. Natrix is the developer of Natrix™ HD Membrane Technology and Advective™ Chromatography, which is now available in NatriFlo™ flow-through chromatography products for biomolecule polish applications.

The Natrix portfolio complements JSR Life Sciences’ existing bioprocess technology including its Amsphere™ Protein A media for monoclonal antibody purification, which the company successfully launched last year.

“We are very pleased to enter into this partnership with Natrix,” said Eric R. Johnson, president of JSR Micro, Inc. in the US. “Over the past decade, Natrix has developed and proven its proprietary technology, which is now ready for industry adoption. The Natrix platform combines with our existing product lines to enable JSR to offer a complete downstream tool set for the bioprocess industry.”

Natrix™ HD Membrane Technology combines binding capacity that exceeds conventional resin-based columns and fast flow-rates typical of membrane adsorbers. The versatile technology can be deployed in flow-through or bind-elute mode. Natrix will launch its NatriFlo™ flow-through product line for polish applications in September. NatriFlo delivers best-in-class HCP removal, DNA removal and Viral Clearance, even with the most challenging feedstreams, and with plenty of capacity to spare. Natrix will launch its NatriPur™ bind-elute chromatography products in 2014.

“Natrix technology enables biomolecule developers and manufacturers to achieve a new level of low-cost, highly flexible productivity in their purification operations. We are excited to partner with JSR Life Sciences to bring these products to market,” said John Chickosky, Natrix Separations president & CEO. “Already, customers around the world have expressed great interest in simplifying and adding flexibility to their downstream operations with Natrix technology, and JSR’s global presence and strength makes them a perfect partner to serve those customers.”

JSR Life Sciences Corporation (JLS) has set out for a unique life sciences company which continuously provides outstanding materials and applications for customers in life science and medical industries. Our products are based on prominent material technologies cultivated for a long time in JSR and incorporated with state-of-the-art technologies acquired through our global network.

Natrix Separations, based in Burlington, Ontario, Canada, is the developer of Natrix™ HD Membrane Technology for the purification of biopharmaceuticals. Natrix™ HD Membrane Technology combines binding capacity that exceeds conventional resin-based chromatography columns and fast flow-rates typical of membrane adsorbers for both flow-through and bind-elute capture applications. Natrix products enable biopharmaceutical manufacturers with a complete set of purification tools that overcome the efficiency, speed, and flexibility barriers imposed by conventional capital-intensive approaches to chromatography. Natrix products feature well-established industry-standard chemistries and are scalable from R&D to commercial manufacturing.

Suggested Articles

An assessment looking at 12 health systems that allow patients to download their health records to their smartphones via APIs finds modest uptake.

The National Institutes of Health-led All of Us precision medicine project has enrolled 230,000 participants with another 40,000 people registered.

Hospitals must pursue a deliberate strategy for managing their public image—and a powerful tool for doing so is inpatient clinical data registries.